Published in Hum Mol Genet on January 24, 2009
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Nature meets nurture: molecular genetics of gastric cancer. Hum Genet (2009) 1.87
Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev (2014) 1.73
Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol (2012) 1.53
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet (2015) 1.36
A mobile threat to genome stability: The impact of non-LTR retrotransposons upon the human genome. Semin Cancer Biol (2010) 1.34
Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol (2015) 1.17
Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer (2010) 1.15
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch (2014) 1.15
Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet (2009) 1.13
Genomic profile analysis of diffuse-type gastric cancers. Genome Biol (2014) 1.07
Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer (2012) 1.03
Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. Cancer Genet Cytogenet (2010) 0.97
E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer. PLoS One (2012) 0.91
N-myc downstream regulated gene 1 (NDRG1) promotes metastasis of human scirrhous gastric cancer cells through epithelial mesenchymal transition. PLoS One (2012) 0.90
Germline mutations in MAP3K6 are associated with familial gastric cancer. PLoS Genet (2014) 0.90
Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. Fam Cancer (2013) 0.88
Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract (2012) 0.86
Hereditary gastric cancer. Pathologe (2012) 0.85
Hereditary diffuse gastric cancer: What the clinician should know. World J Gastrointest Oncol (2015) 0.85
Hereditary diffuse gastric cancer: multidisciplinary case report with review of the literature. Patholog Res Int (2011) 0.84
CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland. Fam Cancer (2010) 0.83
Hereditary diffuse gastric cancer in a Japanese family with a large deletion involving CDH1. Gastric Cancer (2013) 0.82
Polymorphisms in the 3'-untranslated region of the CDH1 gene are a risk factor for primary gastric diffuse large B-cell lymphoma. Haematologica (2011) 0.81
Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene. Gastric Cancer (2013) 0.80
Gastric biomarkers: a global review. World J Surg Oncol (2016) 0.79
Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). Eur J Hum Genet (2013) 0.79
Altering Genomic Integrity: Heavy Metal Exposure Promotes Transposable Element-Mediated Damage. Biol Trace Elem Res (2015) 0.78
[Hereditary gastric cancer]. Pathologe (2010) 0.78
Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. Fam Cancer (2015) 0.78
Genetic screening analysis of patients with hereditary diffuse gastric cancer from northern and northeastern Brazil. Hered Cancer Clin Pract (2014) 0.77
A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer. BMC Med Genomics (2016) 0.76
Familial Gastric Cancers. Oncologist (2015) 0.75
Sequence-based detection of mutations in cadherin 1 to determine the prevalence of germline mutations in patients with invasive lobular carcinoma of the breast. Hered Cancer Clin Pract (2014) 0.75
Hereditary cancer risk assessment: challenges for the next-gen sequencing era. Front Oncol (2015) 0.75
Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients. Endosc Int Open (2016) 0.75
Transcriptional regulation of E-cadherin and oncoprotein E7 by valproic acid in HPV positive cell lines. Iran J Basic Med Sci (2016) 0.75
Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. Eur J Hum Genet (2014) 0.75
A novel mutation in the CDH1 gene in a Spanish family with hereditary diffuse gastric cancer. Springerplus (2016) 0.75
The identification and management of hereditary diffuse gastric cancer in a large Jordanian family. Fam Cancer (2011) 0.75
Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. Eur J Hum Genet (2017) 0.75
Paired-end mapping reveals extensive structural variation in the human genome. Science (2007) 30.46
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res (2002) 16.02
E-cadherin germline mutations in familial gastric cancer. Nature (1998) 6.72
The fine-scale and complex architecture of human copy-number variation. Am J Hum Genet (2008) 5.08
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet (1991) 3.48
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med (2001) 3.27
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology (2001) 3.00
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet (2004) 2.95
MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet (1998) 2.73
Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet (1999) 2.41
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res (1998) 2.20
Saccharomyces cerevisiae Sae2- and Tel1-dependent single-strand DNA formation at DNA break promotes microhomology-mediated end joining. Genetics (2007) 2.19
Distinct DNA sequence and structure requirements for the two steps of V(D)J recombination signal cleavage. EMBO J (1996) 2.13
Cryptic signals and the fidelity of V(D)J joining. Mol Cell Biol (1997) 1.71
Characterization of hMLH1 and hMSH2 gene dosage alterations in Lynch syndrome patients. Gastroenterology (2005) 1.65
Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol (1999) 1.61
Hypotrichosis with juvenile macular dystrophy is caused by a mutation in CDH3, encoding P-cadherin. Nat Genet (2001) 1.53
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res (2005) 1.46
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat (2002) 1.44
MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res (2002) 1.41
Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol (2005) 1.39
Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study. Hum Mutat (2005) 1.39
Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet (2004) 1.38
Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer (2001) 1.35
Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat (2003) 1.32
Small deletion variants have stable breakpoints commonly associated with alu elements. PLoS One (2008) 1.30
Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol (2006) 1.29
Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol (2008) 1.24
E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer (2004) 1.17
Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. J Med Genet (2005) 1.16
A familial inverted duplication/deletion of 2p25.1-25.3 provides new clues on the genesis of inverted duplications. Eur J Hum Genet (2008) 1.11
Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome). J Med Genet (2005) 1.10
Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer (2008) 1.06
Ionizing radiation and restriction enzymes induce microhomology-mediated illegitimate recombination in Saccharomyces cerevisiae. Nucleic Acids Res (2007) 1.01
The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet (2006) 1.00
Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene (2004) 0.97
Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. Hum Mol Genet (2008) 0.96
Evidence for non-homologous end joining and non-allelic homologous recombination in atypical NF1 microdeletions. Hum Genet (2004) 0.93
Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations. Cancer Lett (2006) 0.93
Low frequency of large genomic rearrangements of BRCA1 and BRCA2 in western Denmark. Cancer Genet Cytogenet (2006) 0.91
E-cadherin is not frequently mutated in hereditary gastric cancer. J Med Genet (2001) 0.89
Hereditary diffuse gastric cancer and E-cadherin: description of the first germline mutation in an Italian family. Eur J Surg Oncol (2006) 0.86
A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes Chromosomes Cancer (2006) 0.84
Identification of Alu elements mediating a partial PMP22 deletion. Neurogenetics (2006) 0.81
Germline translocations in mice: unique tools for analyzing gene function and long-distance regulatory mechanisms. J Natl Cancer Inst Monogr (2008) 0.81
The Bioperl toolkit: Perl modules for the life sciences. Genome Res (2002) 58.63
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Whole-genome shotgun assembly and analysis of the genome of Fugu rubripes. Science (2002) 20.59
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 5.58
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science (2013) 5.34
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol (2011) 4.66
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics (2010) 4.02
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation (2005) 3.54
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Biopipe: a flexible framework for protocol-based bioinformatics analysis. Genome Res (2003) 3.45
Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res (2009) 3.44
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol (2006) 3.42
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
The IKMC web portal: a central point of entry to data and resources from the International Knockout Mouse Consortium. Nucleic Acids Res (2010) 3.23
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg (2012) 3.15
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
p300/CBP and cancer. Oncogene (2004) 3.13
Osteopontin expression correlates with melanoma invasion. J Invest Dermatol (2005) 3.13
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature (2012) 3.08
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology (2002) 2.85
The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer (2005) 2.83
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene (2003) 2.56
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg (2010) 2.27
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med (2011) 2.25
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
Comparative study of laparoscopy-assisted distal gastrectomy and open distal gastrectomy. J Am Coll Surg (2006) 2.23
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes. Oncogene (2003) 2.21
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18